ACHKF: AI 评分 46/100 — AI 分析 (4月 2026)

Achiko AG is a healthcare company focused on developing diagnostic solutions, including the AptameX rapid Covid-19 test and the Teman Sehat mobile application. The company also provides payment solutions and develops game software.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Achiko AG is a Swiss-based healthcare company specializing in disruptive diagnostic solutions, including the AptameX rapid COVID-19 test utilizing DNA aptamers. The company also offers the Teman Sehat mobile health passport and Mimopay, a secure payment platform for digital content, operating primarily in Indonesia and internationally.

ACHKF是做什么的？

Achiko AG, incorporated in 2018 and headquartered in Zurich, Switzerland, is a healthcare company focused on developing and commercializing disruptive diagnostic solutions. The company's primary focus is on its AptameX technology, a rapid diagnostic test for the SARS-CoV-2 virus that utilizes DNA aptamers instead of traditional antibodies. This innovative approach aims to provide a faster and potentially more cost-effective testing solution. In addition to AptameX, Achiko offers Teman Sehat, a mobile application designed as a health passport and check-in system, particularly relevant in the context of pandemic management and public health monitoring. Beyond diagnostics, Achiko AG also operates Mimopay, a secure payment solution tailored for game publishers and application developers. Mimopay enables these businesses to accept a wide range of payment methods for digital content and goods. The company also engages in game software development, diversifying its revenue streams and leveraging its technological capabilities. Achiko's operations are primarily based in Indonesia and internationally, reflecting its strategy to address global healthcare and digital payment needs. The company's relatively small size, with approximately 10 employees, suggests a focus on strategic partnerships and efficient resource allocation to achieve its goals.

ACHKF的投资论点是什么？

Achiko AG presents a high-risk, high-reward investment opportunity in the healthcare and digital solutions space. The company's AptameX rapid COVID-19 test offers potential as a disruptive diagnostic tool, although its market acceptance and regulatory approvals remain uncertain. The Teman Sehat mobile application could gain traction as a health passport solution, particularly in regions with evolving public health requirements. However, Achiko's financial performance, characterized by a negative profit margin of -14913.2% and a small market capitalization, indicates significant challenges. The company's success hinges on its ability to successfully commercialize its products, secure funding, and navigate a competitive landscape. Investors should carefully consider the risks associated with Achiko's OTC listing and limited financial disclosure.

ACHKF在哪个行业运营？

Achiko AG operates within the healthcare information services industry, a sector experiencing rapid growth driven by technological advancements and increasing demand for efficient diagnostic and digital health solutions. The COVID-19 pandemic has accelerated the adoption of rapid testing and mobile health applications, creating opportunities for companies like Achiko. However, the industry is also highly competitive, with established players such as ALSE (Alseres Pharmaceuticals), AQQRF (AdvanCell Isotopes), FLURF (Flora Growth Corp), LNDZF (Landa App), and MSITF (MITS Inc) and numerous startups vying for market share. Achiko's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strategic partnerships.

Medical - Healthcare Information Services

Healthcare

ACHKF有哪些增长机遇？

Expansion of AptameX Testing: Achiko has the opportunity to expand the market reach of its AptameX rapid COVID-19 test. The global market for COVID-19 diagnostics is expected to remain substantial, driven by ongoing testing needs and the emergence of new variants. Securing regulatory approvals in key markets and establishing distribution partnerships could significantly increase AptameX sales. The timeline for this growth opportunity is ongoing, as the pandemic continues to evolve and testing remains a critical tool for managing its spread.
Adoption of Teman Sehat Mobile App: Achiko can capitalize on the growing demand for digital health solutions by promoting its Teman Sehat mobile application. As governments and organizations seek ways to manage public health and facilitate safe travel, Teman Sehat could gain traction as a health passport and check-in system. Partnering with airlines, event organizers, and government agencies could accelerate adoption. The timeline for this growth opportunity is near-term, as the need for digital health solutions persists.
Diversification of Diagnostic Solutions: Achiko can leverage its AptameX technology to develop diagnostic tests for other infectious diseases and health conditions. Expanding its product portfolio beyond COVID-19 would reduce its reliance on a single market and create new revenue streams. The global diagnostics market is vast and growing, offering numerous opportunities for innovative testing solutions. The timeline for this growth opportunity is medium-term, as it requires research, development, and clinical validation.
Strategic Partnerships and Acquisitions: Achiko can accelerate its growth by forming strategic partnerships with established healthcare companies or acquiring complementary businesses. Collaborations with larger players could provide access to wider distribution networks, regulatory expertise, and financial resources. Acquisitions could expand Achiko's product portfolio and technological capabilities. The timeline for this growth opportunity is ongoing, as Achiko continuously seeks opportunities to enhance its competitive position.
Expansion of Mimopay Payment Solutions: Achiko can expand its Mimopay payment solutions to serve a wider range of digital content providers and application developers. The global market for digital payments is experiencing rapid growth, driven by the increasing adoption of online gaming, e-commerce, and mobile applications. By offering secure and convenient payment options, Mimopay can attract new customers and increase its transaction volume. The timeline for this growth opportunity is medium-term, as it requires ongoing investment in technology and marketing.

Achiko AG operates with a small team of 10 employees, indicating a lean operational structure.
The company's lead product, AptameX, is a rapid test for SARS-CoV-2 using DNA aptamers, potentially offering a faster and more cost-effective diagnostic solution.
Achiko's gross margin stands at 37.3%, reflecting the potential profitability of its diagnostic and digital solutions.
The company's negative P/E ratio of -0.04 and profit margin of -14913.2% highlight its current financial challenges.
Achiko AG's beta of -0.39 suggests a low correlation with the overall market, potentially offering some diversification benefits.

ACHKF提供哪些产品和服务？

Develops the AptameX rapid test for detecting the SARS-CoV-2 virus using DNA aptamers.
Offers the Teman Sehat mobile application for health passport and check-in functionalities.
Provides Mimopay, a secure payment solution for game publishers and application developers.
Enables acceptance of various payment methods for digital content and goods.
Engages in game software development.
Focuses on disruptive diagnostic solutions in Indonesia and internationally.

ACHKF如何赚钱？

Generates revenue from the sale of AptameX rapid COVID-19 tests.
Offers Teman Sehat as a subscription or licensing model for organizations and governments.
Earns transaction fees from Mimopay payment processing for digital content and goods.
Derives income from the sale of game software.

Healthcare providers and testing centers using AptameX for rapid COVID-19 detection.
Organizations and government agencies implementing Teman Sehat for health monitoring and check-in.
Game publishers and application developers utilizing Mimopay for secure payment processing.
Consumers purchasing game software developed by Achiko.

Proprietary AptameX technology using DNA aptamers for rapid diagnostics.
First-mover advantage in developing a mobile health passport solution with Teman Sehat.
Established relationships with game publishers and application developers through Mimopay.
Geographic focus on Indonesia and international markets with specific local expertise.

什么因素可能推动ACHKF股价上涨？

Upcoming: Regulatory approvals for AptameX in key markets, potentially expanding its commercial reach.
Upcoming: Strategic partnerships with healthcare providers or distributors to increase AptameX sales.
Ongoing: Continued adoption of Teman Sehat mobile app by organizations and government agencies.
Ongoing: Expansion of Mimopay payment solutions to new digital content providers.
Ongoing: Development of new diagnostic tests based on the AptameX technology.

ACHKF的主要风险是什么？

Potential: Competition from established healthcare companies and diagnostic providers.
Potential: Regulatory hurdles and delays in obtaining approvals for AptameX.
Potential: Changes in public health policies and testing requirements.
Ongoing: Limited financial resources and reliance on external funding.
Ongoing: OTC listing with limited liquidity and disclosure requirements.

ACHKF的核心优势是什么？

Innovative AptameX technology for rapid COVID-19 testing.
Teman Sehat mobile app addresses the need for digital health solutions.
Mimopay provides a secure payment platform for digital content.
Geographic focus on Indonesia and international markets.

ACHKF的劣势是什么？

Limited financial resources and small market capitalization.
Negative profit margin and reliance on external funding.
OTC listing with limited liquidity and disclosure requirements.
Dependence on the success of a few key products.

ACHKF有哪些机遇？

Expansion of AptameX testing to new markets and applications.
Increased adoption of Teman Sehat as a health passport solution.
Diversification of diagnostic solutions beyond COVID-19.
Strategic partnerships and acquisitions to accelerate growth.

ACHKF面临哪些威胁？

Competition from established healthcare companies and diagnostic providers.
Regulatory hurdles and delays in obtaining approvals for AptameX.
Changes in public health policies and testing requirements.
Economic downturns and reduced consumer spending on digital content.

ACHKF的竞争对手是谁？

Alseres Pharmaceuticals — Focuses on CNS disorders, different therapeutic area. — (ALSE)
AdvanCell Isotopes — Specializes in radioisotopes, a different diagnostic modality. — (AQQRF)
Flora Growth Corp — Operates in the cannabis industry, unrelated to diagnostics. — (FLURF)
Landa App — Focuses on real estate investment, a different market. — (LNDZF)
MITS Inc — Provides IT solutions, not directly involved in healthcare diagnostics. — (MSITF)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Wern-Yi Goh
Headquarters: Zurich, CH
Employees: 10
Founded: 2021

AI Insight

AI analysis pending for ACHKF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Achiko AG do?

Achiko AG is a healthcare company focused on developing and commercializing disruptive diagnostic and digital solutions. Its primary product is AptameX, a rapid test for detecting the SARS-CoV-2 virus using DNA aptamers. The company also offers Teman Sehat, a mobile application designed as a health passport and check-in system. Additionally, Achiko provides Mimopay, a secure payment solution for game publishers and application developers. The company operates primarily in Indonesia and internationally, targeting the healthcare and digital payment markets.

What do analysts say about ACHKF stock?

As of 2026-03-16, formal analyst coverage of ACHKF is limited due to its OTC listing and small market capitalization. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, may not be readily available or reliable due to the company's financial challenges. Growth considerations center on the successful commercialization of AptameX, adoption of Teman Sehat, and expansion of Mimopay. Investors should conduct their own independent research and consider the risks associated with investing in OTC stocks.

What are the main risks for ACHKF?

The main risks for ACHKF include its limited financial resources, reliance on external funding, and OTC listing with limited liquidity and disclosure requirements. The company faces competition from established healthcare companies and diagnostic providers, as well as regulatory hurdles in obtaining approvals for AptameX. Changes in public health policies and testing requirements could also impact the demand for its products. Investors should carefully consider these risks before investing in ACHKF.